On the other hand, a very recent analysis of CLL-associated macrophages in bone marrow biopsies obtained from CLL patients during ibrutinib treatment suggests that ibrutinib may disrupt CLL-macrophage interactions on the basis of a significant decrease in CD68+ cellular extension and a reduction of CXCL13 secretion [28]. Here, CXCL13 is linked to B-cell chronic lymphocytic leukemia.